Showing posts with label iloperidone. Show all posts
Showing posts with label iloperidone. Show all posts

Saturday, May 11, 2024

Iloperidone for Bipolar Disorder


Most recent medication to be approved for bipolar disorder is an atypical anti-psychotic, Iloperidone. To be more specific, this drug was approved by the US Food and Drug Administration for treatment of manic or mixed episodes associated with bipolar I disorder in adults. This can be considered a significant development because new medications and treatments in the field of psychiatry are few.

Iloperidone is an atypical anti-psychotic, with a mixed D2/5HT2A antagonism as its mechanism of action. It was first approved for acute treatment of schizophrenia in adults. 


References:

  •  Vanda Pharmaceuticals' Fanapt (iloperidone) receives US FDA approval for the acute treatment of bipolar I disorder. News release. Vanda Pharmaceuticals Inc. April 2, 2024. Accessed April 2, 2024. https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-fanapt-iloperidone-receives-us-fda-approval-for-the-acute-treatment-of-bipolar-i-disorder-302106405.html
  • Torres R, Czeisler EL, Chadwick SR, Stahl SM, Smieszek SP, Xiao C, Polymeropoulos CM, Birznieks G, Polymeropoulos MH. Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2024 Jan 15;85(1):23m14966. doi: 10.4088/JCP.23m14966. PMID: 38236020.